


# Opportunity to generate competition in the biologics space with more than 1000 biosimilar medicines covering over 10 therapeutic areas

- A. Canada
- B. USA
- C. Mexico
- D. Brazil
- E. Argentina
- F. Chile
- G. European Union
- H. UK
- I. Switzerland
- J. Serbia
- K. Turkey
- L. Montenegro
- M. Jordan
- N. Saudi Arabia
- O. Egypt
- P. Morocco
- Q. South Africa
- R. Japan
- S. South Korea
- T. India
- U. Malaysia
- V. Chinese Taipei
- W. Australia
- X. Singapore

 Number of biosimilar approvals

Source of data: IGBA membership and National Regulatory Authorities

